Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 565 | 2018 |
Metformin: multi-faceted protection against cancer S Del Barco, A Vazquez-Martin, S Cufí, C Oliveras-Ferraros, ... Oncotarget 2 (12), 896, 2011 | 386 | 2011 |
STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis N Priego, L Zhu, C Monteiro, M Mulders, D Wasilewski, W Bindeman, ... Nature Medicine 24 (7), 1024-1035, 2018 | 367 | 2018 |
Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer M Provencio, E Nadal, JL González-Larriba, A Martínez-Martí, R Bernabé, ... New England Journal of Medicine 389 (6), 504-513, 2023 | 202 | 2023 |
Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy J Bosch-Barrera, JA Menendez Cancer treatment reviews 41 (6), 540-546, 2015 | 171 | 2015 |
Metformin-induced preferential killing of breast cancer initiating CD44+ CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast … S Cufí, B Corominas-Faja, A Vazquez-Martin, C Oliveras-Ferraros, ... Oncotarget 3 (4), 395, 2012 | 168 | 2012 |
Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity S Verdura, E Cuyàs, E Cortada, J Brunet, E López Bonet, B Martin Castillo, ... Aging-us, 2020, vol. 12, num. 1, p. 8-34, 2020 | 123 | 2020 |
Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells B Corominas Faja, E Cuyàs, J Gumuzio, J Bosch Barrera, O Leis, ... Oncotarget, 2014, vol. 5, núm. 18, p. 8306-8316, 2014 | 121 | 2014 |
Targeting STAT3 with silibinin to improve cancer therapeutics J Bosch-Barrera, B Queralt, JA Menendez Cancer treatment reviews 58, 61-69, 2017 | 107 | 2017 |
Metformin is a direct SIRT1-activating compound: computational modeling and experimental validation E Cuyàs, S Verdura, L Llorach-Parés, S Fernández-Arroyo, J Joven, ... Frontiers in endocrinology 9, 657, 2018 | 106 | 2018 |
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations A Vazquez-Martin, S Cufí, C Oliveras-Ferraros, VZ Torres-Garcia, ... Scientific reports 3 (1), 1-15, 2013 | 99 | 2013 |
Stem cell-like ALDHbright cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the … B Corominas-Faja, C Oliveras-Ferraros, E Cuyas, A Segura-Carretero, ... Cell cycle 12 (21), 3390-3404, 2013 | 97 | 2013 |
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells P Muñoz-Guardiola, J Casas, E Megías-Roda, S Solé, H Perez-Montoyo, ... Autophagy 17 (6), 1349-1366, 2021 | 90 | 2021 |
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo S Cufí, R Bonavia, A Vazquez-Martin, C Oliveras-Ferraros, ... Scientific reports 3 (1), 2459, 2013 | 77 | 2013 |
Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205 S Cufi, A Vazquez-Martin, C Oliveras-Ferraros, R Quirantes, ... Cell cycle 11 (6), 1235-1246, 2012 | 77 | 2012 |
Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR … S Cufí, R Bonavia, A Vazquez-Martin, B Corominas-Faja, ... Food and chemical toxicology 60, 360-368, 2013 | 76 | 2013 |
Silibinin is a direct inhibitor of STAT3 S Verdura, E Cuyàs, L Llorach-Parés, A Pérez-Sánchez, V Micol, ... Food and Chemical Toxicology 116, 161-172, 2018 | 74 | 2018 |
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer N Karachaliou, J Codony-Servat, C Teixidó, S Pilotto, A Drozdowskyj, ... Scientific reports 5 (1), 17499, 2015 | 72 | 2015 |
STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer E Cuyas, A Pérez-Sánchez, V Micol, JA Menendez, J Bosch-Barrera Cell Cycle 15 (24), 3413-3418, 2016 | 68 | 2016 |
Nivolumab+ chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from … M Provencio-Pulla, E Nadal, JLG Larriba, A Martinez-Marti, R Bernabé, ... Journal of Clinical Oncology 40 (16_suppl), 8501-8501, 2022 | 65 | 2022 |